Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.

FDA Drug Approvals

Med Alerts

Namzaric® (memantine and donepezil hydrochloride) extended release capsules

Approval Date: Dec 2023

Note: First-Time Generic

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Zepbound (tirzepatide) injection

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

Zituvimet (sitagliptin and metformin hydrochloride) tablets

Approval Date: Nov 2023

Note: New Product

Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes

Voquezna (vonoprazan fumarate) tablets

Approval Date: Nov 2023

Note: New Product

Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis

Zymfentra (infliximab-dyyb) injection

Approval Date: Oct 2023

Note: New Product

Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously

Omvoh (mirikizumab-mrkz) injection

Approval Date: Oct 2023

Note: New Product

A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis

Wezlana (ustekinumab-auub) injection

Approval Date: Oct 2023

Note: Biosimilar

A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

Velsipity (estrasimod) tablets

Approval Date: Oct 2023

Note: New Product

Indicated for the treatment of moderate to severe ulcerative colitis

Cosentyx® (secukinumab) injection for intravenous use

Approval Date: Oct 2023

Note: New Dosage or Formulation

Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation

Bimzelx® (bimekizumab-bkzx) injection for subcutaneous use

Approval Date: Oct 2023

Note: New Product

Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Combogesic® IV (acetaminophen and ibuprofen)

Approval Date: Oct 2023

Note: Dosage or Formulation

Indicated for the short term management of mild to moderate acute pain, and the management of moderate to severe pain as an adjunct to opioid analgesics, this drug is now available in an intravenous formulation

Tofidence (tocilizumab-bavi) injection 

Approval Date: Sep 2023

Note: New Product

Indicated for the treatment of rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)

Xeljanz (tofacitinib) oral solution

Approval Date: Sep 2023

Note: First-Time Generic

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis

Exxua (gepirone) extended-release tablets

Approval Date: Sep 2023

Note: New Product

Indicated for the treatment of major depressive disorder (MDD), a first-in-class drug that selectively targets the serotonin 1A receptor

Lexette (halobetasol propionate) topical foam

Approval Date: Aug 2023

Note: First-Time Generic

Indicated for the topical treatment of plaque psoriasis

Onglyza (saxagliptin) tablets

Approval Date: Jul 2023

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Kombiglyze® XR (saxagliptin and metformin hydrochloride) extended-release tablets

Approval Date: Jul 2023

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

RiVive (naloxone hydrochloride) nasal spray

Approval Date: Jul 2023

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA

Spiriva® HandiHaler (tiotropium bromide) inhalation powder

Approval Date: Jun 2023

Note: First-Time Generic

For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Katerzia® (amlodipine benzoate) oral suspension

Approval Date: Jun 2023

Note: First-Time Generic

For the treatment of hypertension and coronary artery disease

Fleqsuvy (baclofen) oral suspension

Approval Date: Jun 2023

Note: First-Time Generic

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Diastat® AcuDial (diazepam) rectal gel delivery system

Approval Date: May 2023

Note: First-Time Generic

Indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity

Celontin® (methsuximide) capsules

Approval Date: May 2023

Note: First-Time Generic

Indicated for the control of absence (petit mal) seizures that are refractory to other drugs

Yuflyma (adalimumab-aaty) injection

Approval Date: May 2023

Note: New Product

A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

Paxlovid (nirmatrelvir and ritonavir) tablets

Approval Date: May 2023

Note: New Product

Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19

Inpefa (sotagliflozin) tablets

Approval Date: May 2023

Note: New Product

Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes

Opvee® (nalmefene hydrochloride) nasal spray

Approval Date: May 2023

Note: New Product

Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use

Brixadi (buprenorphine) extended-release injection

Approval Date: May 2023

Note: New Product

Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages

Motpoly XR (lacosamide)

Approval Date: May 2023

Note: New Product

Indicated for the treatment of partial-onset seizures in adults

Abilify Asimtufii® (aripiprazole)

Approval Date: Apr 2023

Note: New Formulation

Indicated for the treatment of schizophrenia or as maintenance monotherapy treatment of bipolar I disorder

Uzedy (risperidone) extended-release injectable suspension

Approval Date: Apr 2023

Note: New Formulation

Indicated for the treatment of schizophrenia in adults

Zavzpret (zavegepant) nasal spray

Approval Date: Mar 2023

Note: New Product

Indicated for the acute treatment of migraine with or without aura

Combogesic® (acetaminophen and ibuprofen) tablets

Approval Date: Mar 2023

Note: New Product

Indicated for the short term management of mild to moderate acute pain

Trokendi XR (topiramate) extended-release capsules

Approval Date: Feb 2023

Note: First-Time Generic

Indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures, adjunctive therapy for partial-onset, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome (LGS), and preventive treatment of migraine

Advil Dual Action (acetaminophen and ibuprofen) tablets (OTC)

Approval Date: Feb 2023

Note: First-Time Generic

Temporarily relieves minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches, minor pain of arthritis

Leqembi (lecnemab-irmb) injection

Approval Date: Jan 2023

Note: New Product

Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease

Sunlenca® (lenacapavir) tablets

Approval Date: Dec 2022

Note: New Product

In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection

Idacio® (adalimumab-aacf) injection

Approval Date: Dec 2022

Note: New Product

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis

Tzield® (teplizumab-mzwv) injection

Approval Date: Nov 2022

Note: New Product

A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.

Daliresp® (roflumilast) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

Tazorac® (tazarotene) gel

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement

Byvalson (nebivolol and valsartan) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the treatment of hypertension, to lower blood pressure

Prezista® (darunavir) tablets

Approval Date: Sep 2022

Note: First-Time Generic

Indicated for the treatment of HIV-1 infection

Sotyktu (deucravacitnib) tablets

Approval Date: Sep 2022

Note: New Product

Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Jardiance® (empagliflozin) tablets

Approval Date: Aug 2022

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Rexulti® (brexpiprazole) tablets

Approval Date: Aug 2022

Note: First-Time Generic

Indicated for the adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Banzel® (rufinamide) tablets

Approval Date: Aug 2022

Note: First-Time Generic

Indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome

Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets

Approval Date: Aug 2022

Note: New Product

For the treatment of major depressive disorder, this antidepressant is notable for producing antidepressant results within one week

Synjardy® (empagliflozin and metformin hydrochloride) tablets

Approval Date: Jul 2022

Note: First-Time Generic

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Edarbi® (azilsartan medoxomil) tablets

Approval Date: Jul 2022

Note: First-Time Generic

Indicated for the treatment of hypertension to lower blood pressure

Nalfon® (fenoprofen calcium) tablets

Approval Date: Jul 2022

Note: First-Time Generic

An NSAID used for the relief of mild to moderate pain or relief in the signs and symptoms of rheumatoid arthritis or osteoarthritis

Zoryve (roflumilast) cream

Approval Date: Jul 2022

Note: New Product

Indicated for topical treatment of plaque psoriasis

Zonisade (zonisamide) oral suspension

Approval Date: Jul 2022

Note: New Dosage or Formulation

Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.

Briviact (brivaracetam) tablets

Approval Date: Jun 2022

Note: First-Time Generic

Indicated for the treatment of partial-onset seizures.

Riabni (rituximab-arrx)

Approval Date: Jun 2022

Note: New Indication

A biosimilar to Rituxan® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.

Skyrizi® (risankizumab-rzza) injection

Approval Date: Jun 2022

Note: New Indication

Approved for its third indication for moderately to severely active Crohn’s disease, in addition to existing indications for moderate-to-severe plaque psoriasis and active psoriatic arthritis.

Vtama® (tapinarof) cream

Approval Date: May 2022

Note: New Product

A steroid-free topical indicated for treatment of plaque psoriasis

Olumiant® (baricitinib)

Approval Date: May 2022

Note: New Product

Indicated for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, and other assistance with breathing

Mounjaro (tirzepatide) injection

Approval Date: May 2022

Note: New Product

Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise

Igalmi (dexmedetomidine) sublingual film

Approval Date: Apr 2022

Note: New Product

Indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder

Medication Name

Approval Date

Category

Description

Namzaric® (memantine and donepezil hydrochloride) extended release capsules

Dec 2023

Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Note: First-Time Generic

Zepbound (tirzepatide) injection

Nov 2023

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults, or overweight adults with at least one weight-related comorbidity

Note: New Product

Zituvimet (sitagliptin and metformin hydrochloride) tablets

Nov 2023

Indicated as an adjunct to diet and exercise to improve glycemic control of type 2 diabetes

Note: New Product

Voquezna (vonoprazan fumarate) tablets

Nov 2023

Indicated for erosive esophagitis and the relief of heartburn associated with erosive esophagitis

Note: New Product

Zymfentra (infliximab-dyyb) injection

Oct 2023

Indicated for the maintenance treatment of moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, following treatment with an infliximab product administered intravenously

Note: New Product

Omvoh (mirikizumab-mrkz) injection

Oct 2023

A first-in-class agent indicated for the treatment of moderate to severe ulcerative colitis

Note: New Product

Wezlana (ustekinumab-auub) injection

Oct 2023

A biosimilar to Stelara, indicated for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

Note: Biosimilar

Velsipity (estrasimod) tablets

Oct 2023

Indicated for the treatment of moderate to severe ulcerative colitis

Note: New Product

Cosentyx® (secukinumab) injection for intravenous use

Oct 2023

Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation

Note: New Dosage or Formulation

Bimzelx® (bimekizumab-bkzx) injection for subcutaneous use

Oct 2023

Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Note: New Product

Combogesic® IV (acetaminophen and ibuprofen)

Oct 2023

Indicated for the short term management of mild to moderate acute pain, and the management of moderate to severe pain as an adjunct to opioid analgesics, this drug is now available in an intravenous formulation

Note: Dosage or Formulation

Tofidence (tocilizumab-bavi) injection 

Sep 2023

Indicated for the treatment of rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)

Note: New Product

Xeljanz (tofacitinib) oral solution

Sep 2023

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis

Note: First-Time Generic

Exxua (gepirone) extended-release tablets

Sep 2023

Indicated for the treatment of major depressive disorder (MDD), a first-in-class drug that selectively targets the serotonin 1A receptor

Note: New Product

Lexette (halobetasol propionate) topical foam

Aug 2023

Indicated for the topical treatment of plaque psoriasis

Note: First-Time Generic

Onglyza (saxagliptin) tablets

Jul 2023

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Note: First-Time Generic

Kombiglyze® XR (saxagliptin and metformin hydrochloride) extended-release tablets

Jul 2023

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

Note: First-Time Generic

RiVive (naloxone hydrochloride) nasal spray

Jul 2023

Indicated for the emergency treatment of known or suspected opioid overdose, this drug is the second over-the-counter nonprescription opioid overdose drug approved by the FDA

Note: New Product

Spiriva® HandiHaler (tiotropium bromide) inhalation powder

Jun 2023

For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Note: First-Time Generic

Katerzia® (amlodipine benzoate) oral suspension

Jun 2023

For the treatment of hypertension and coronary artery disease

Note: First-Time Generic

Fleqsuvy (baclofen) oral suspension

Jun 2023

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Note: First-Time Generic

Diastat® AcuDial (diazepam) rectal gel delivery system

May 2023

Indicated for the management of selected, refractory, patients with epilepsy, on stable regimens of anti-epileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity

Note: First-Time Generic

Celontin® (methsuximide) capsules

May 2023

Indicated for the control of absence (petit mal) seizures that are refractory to other drugs

Note: First-Time Generic

Yuflyma (adalimumab-aaty) injection

May 2023

A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

Note: New Product

Paxlovid (nirmatrelvir and ritonavir) tablets

May 2023

Indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19

Note: New Product

Inpefa (sotagliflozin) tablets

May 2023

Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes

Note: New Product

Opvee® (nalmefene hydrochloride) nasal spray

May 2023

Indicated for the emergency treatment of known or suspected opioid overdose. This is the first approval of nalmefene hydrochloride nasal spray for health care and community use

Note: New Product

Brixadi (buprenorphine) extended-release injection

May 2023

Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages

Note: New Product

Motpoly XR (lacosamide)

May 2023

Indicated for the treatment of partial-onset seizures in adults

Note: New Product

Abilify Asimtufii® (aripiprazole)

Apr 2023

Indicated for the treatment of schizophrenia or as maintenance monotherapy treatment of bipolar I disorder

Note: New Formulation

Uzedy (risperidone) extended-release injectable suspension

Apr 2023

Indicated for the treatment of schizophrenia in adults

Note: New Formulation

Zavzpret (zavegepant) nasal spray

Mar 2023

Indicated for the acute treatment of migraine with or without aura

Note: New Product

Combogesic® (acetaminophen and ibuprofen) tablets

Mar 2023

Indicated for the short term management of mild to moderate acute pain

Note: New Product

Trokendi XR (topiramate) extended-release capsules

Feb 2023

Indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures, adjunctive therapy for partial-onset, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut syndrome (LGS), and preventive treatment of migraine

Note: First-Time Generic

Advil Dual Action (acetaminophen and ibuprofen) tablets (OTC)

Feb 2023

Temporarily relieves minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches, minor pain of arthritis

Note: First-Time Generic

Leqembi (lecnemab-irmb) injection

Jan 2023

Indicated for the treatment of Alzheimer’s in patients with mild cognitive impairment or mild dementia sage of the disease

Note: New Product

Sunlenca® (lenacapavir) tablets

Dec 2022

In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection

Note: New Product

Idacio® (adalimumab-aacf) injection

Dec 2022

Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis

Note: New Product

Tzield® (teplizumab-mzwv) injection

Nov 2022

A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.

Note: New Product

Daliresp® (roflumilast) tablets

Sep 2022

Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

Note: First-Time Generic

Tazorac® (tazarotene) gel

Sep 2022

Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement

Note: First-Time Generic

Byvalson (nebivolol and valsartan) tablets

Sep 2022

Indicated for the treatment of hypertension, to lower blood pressure

Note: First-Time Generic

Prezista® (darunavir) tablets

Sep 2022

Indicated for the treatment of HIV-1 infection

Note: First-Time Generic

Sotyktu (deucravacitnib) tablets

Sep 2022

Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Note: New Product

Jardiance® (empagliflozin) tablets

Aug 2022

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Note: First-Time Generic

Rexulti® (brexpiprazole) tablets

Aug 2022

Indicated for the adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Note: First-Time Generic

Banzel® (rufinamide) tablets

Aug 2022

Indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome

Note: First-Time Generic

Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets

Aug 2022

For the treatment of major depressive disorder, this antidepressant is notable for producing antidepressant results within one week

Note: New Product

Synjardy® (empagliflozin and metformin hydrochloride) tablets

Jul 2022

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Note: First-Time Generic

Edarbi® (azilsartan medoxomil) tablets

Jul 2022

Indicated for the treatment of hypertension to lower blood pressure

Note: First-Time Generic

Nalfon® (fenoprofen calcium) tablets

Jul 2022

An NSAID used for the relief of mild to moderate pain or relief in the signs and symptoms of rheumatoid arthritis or osteoarthritis

Note: First-Time Generic

Zoryve (roflumilast) cream

Jul 2022

Indicated for topical treatment of plaque psoriasis

Note: New Product

Zonisade (zonisamide) oral suspension

Jul 2022

Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.

Note: New Dosage or Formulation

Briviact (brivaracetam) tablets

Jun 2022

Indicated for the treatment of partial-onset seizures.

Note: First-Time Generic

Riabni (rituximab-arrx)

Jun 2022

A biosimilar to Rituxan® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.

Note: New Indication

Skyrizi® (risankizumab-rzza) injection

Jun 2022

Approved for its third indication for moderately to severely active Crohn’s disease, in addition to existing indications for moderate-to-severe plaque psoriasis and active psoriatic arthritis.

Note: New Indication

Vtama® (tapinarof) cream

May 2022

A steroid-free topical indicated for treatment of plaque psoriasis

Note: New Product

Olumiant® (baricitinib)

May 2022

Indicated for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, and other assistance with breathing

Note: New Product

Mounjaro (tirzepatide) injection

May 2022

Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise

Note: New Product

Igalmi (dexmedetomidine) sublingual film

Apr 2022

Indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder

Note: New Product
lockenvelopephone-handsetmagnifiermenucross-circle